FDA Approves BioForm’s Radiesse Dermal Filler For HIV, Cosmetic Indications
This article was originally published in The Gray Sheet
Executive Summary
BioForm says it will likely go public within the next year following approval of its Radiesse dermal filler for the cosmetic treatment of nasolabial folds and facial wasting in patients with HIV
You may also be interested in...
Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition
Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4
Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition
Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4
Facial Wasting Fillers: CMS Considers Question Of Coverage Qualification
CMS says it is deciding whether reconstructive treatments for facial lipodystrophy syndrome, associated with human immunodeficiency virus medicines, can qualify for Medicare coverage under a statute that excludes cosmetic surgery from the federal program